Nektar Therapeutics
Yahoo Finance • 21 hours ago
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misleading Institutional Shareholders: Levi & Korsinsky
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in Nektar Therapeutics (NASDAQ: NKTR) during the period from February 26, 2025 through December 15, 2025 may wish to evaluate lead plaintiff opportuni... Full story
Yahoo Finance • 2 days ago
ROSEN, A LEADING AND RANKED FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
NEW YORK, April 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates incl... Full story
Yahoo Finance • 4 days ago
DEADLINE ALERT for EOSE, SLNO, NKTR, DRVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
BENSALEM, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story
Yahoo Finance • 5 days ago
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, April 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for vi... Full story
Yahoo Finance • 7 days ago
Nektar Goes Silent: What's Behind The Quiet Period?
(RTTNews) - Nektar Therapeutics (NKTR) entered a quiet period beginning this month as it awaits the trial results for its lead drug candidate, Rezpegaldesleukin, in alopecia areata. Rezpegaldesleukin, also known as Rezpeg, NKTR-358, or fo... Full story
Yahoo Finance • 8 days ago
Holzer & Holzer, LLC Reminds Investors of Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Aquestive Therapeutics, Inc. (AQST), Nektar Therapeutics (NKTR), and Eos Energy Enterprises, Inc. (EOSE)
ATLANTA, April 06, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: Aquestive Therapeutics, Inc. (AQST) The shareholder class... Full story
Yahoo Finance • 11 days ago
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certai... Full story
Yahoo Finance • 12 days ago
DEADLINE ALERT for BSX, EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story
Yahoo Finance • 13 days ago
Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030
Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares,... Full story
Yahoo Finance • 14 days ago
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates incl... Full story
Yahoo Finance • 14 days ago
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Nektar Therapeu... Full story
Yahoo Finance • 17 days ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates incl... Full story
Yahoo Finance • 20 days ago
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates incl... Full story
Yahoo Finance • 22 days ago
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
LOS ANGELES, March 23, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or ot... Full story
Yahoo Finance • 26 days ago
ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates incl... Full story
Yahoo Finance • 28 days ago
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Morgan Stanley upgraded Lemonade (LMND... Full story
Yahoo Finance • 29 days ago
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKTR
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., March 16, 2026. Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ:... Full story
Yahoo Finance • last month
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February... Full story
Yahoo Finance • last month
Nektar Therapeutics Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the NKTR Securities Class Action
SAN DIEGO, March 11, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 2... Full story
Yahoo Finance • last month
NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With Large Losses in Nektar Therapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Nektar Therapeu... Full story
